Imatinib Therapy for Patients with Chronic Myelogenous Leukemia

  title={Imatinib Therapy for Patients with Chronic Myelogenous Leukemia},
  author={Daniel J. DeAngelo and Jerome Ritz},
  journal={Clinical Cancer Research},
  pages={1 - 3}
Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder characterized by the reciprocal translocation involving chromosomes 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL is created and the constitutive activity of this tyrosine kinase plays a central role in 
The transformative journey of chronic myeloid leukemia
The goals of therapy in CML have consequently been completely rewritten and are now focused on the achievement of faster and deeper molecular responses which correlate with better outcomes for patients.
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Imatinib can interfere with T-cell activation in vitro, and its impact on the frequency of opportunistic infections and graft-versus-host or graft-Versus-leukemia reactions after transplantation should be investigated in clinical trials.
Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach
Patient risk profile is an important factor in oncologists’ decisions to prescribe adjuvant imatinib and the long-term use ofImatinib was associated with a reduction in long- term risk of disease recurrence and mortality.
Increasing survival from leukemia among adolescents and adults in Canada: A closer look.
A significant survival advantage for women relative to men was apparent in the 2006-to-2008 period for all leukemias combined and for CLL and CML, and this advantage was greater at older ages.
A review on various targeted anticancer therapies
A newly developed approach namely small molecular sequential dual targeting theragnostic strategy as a generalized class of TAT for the management of most solid malignancies is introduced, which is expected to help improve overall cancer treatability and curability.
Detection of Novel Mutations in the FABP3 Promoter Region and Association Analysis with Intramuscular Fat Content in Pigs
Two novel mutations, g.-114T> C and g.-158T>G were detected by duplicate sequencing of the porcine FABP3 promoter region and were identified as absolute linkage disequilibrium.
MicroRNA 30a Mediated Autophagy and Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients
Both miR-30a and Beclin 1 levels showed a relation with imatinib response and can therefore be put forward as valuable markers for detection of resistance and may also have promising future therapeutic implications.
Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials
It was demonstrated that BCR pathway inhibitors significantly prolonged progression-free survival and overall survival in relapsed/refractory CLL and no statistically significant difference in any aspect of meta-analysis was noted.
Study of Imatinib Cardiotoxicity In Adult Male Rabbits
Cardiotoxicity of Imatinib mesylate have significant cardiotoxicity that alarming oncologists to avoid medication errors with Imb either large dose or for long periods administration that may have resulted in fatalities.


Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months.
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
The problems of conventional prognostic scores that the authors observed in IFN-treated patients support the idea that IFN changes the natural course of CML, and whether and to what extent IFN is superior to HU appears to depend on the degree of WBC suppression by HU-therapy and on the risk profile of the patients.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.
Results demonstrate that patients who respond to DLI generate potent antibody responses to CML-associated antigens, suggesting the development of coordinated T- and B-cell immunity, and identifies clinically relevant targets of the GVL response in vivo.
Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
This analysis provides evidence for a survival advantage with imatinib versus other therapies in chronic-phase CML post-IFN failure, and for a surviving advantage with Imatinib vs IFN in late chronic- phase CML.
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein and it was found that this compound may be useful in the treatment of bcr–abl–positive leukemias.
Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Long-term persistence of PCR-detectable bcr-abl mRNA after allogeneic BMT can be caused by the persistence of CML-derived clonogenic myeloid precursors that have survived the BMT preparative regimen.
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.
During long-term treatment of Philadelphia chromosome-positive chronic myeloid leukemia, interferon alfa-2a induced more karyotypic responses than conventional chemotherapy, delayed disease progression longer, and prolonged overall survival more.
Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy
The results demonstrate that PBMC BCR / ABL mRNA levels correlate well with response to STI-571, demonstrating that this non-invasive, rapid and sensitive PCR-based assay can be used to monitor response toSTI-572.